Amgen 2010 Annual Report Download - page 148

Download and view the complete annual report

Please find page 148 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

15. Financing arrangements
The following table reflects the carrying values and the fixed contractual coupon rates of our borrowings under
our various financing arrangements as of December 31, 2010 and 2009 (dollar amounts in millions):
2010 2009
0.125% convertible notes due 2011 (2011 Convertible Notes) ..................... $ 2,488 $ 2,342
0.375% convertible notes due 2013 (2013 Convertible Notes) ..................... 2,213 2,088
5.85% notes due 2017 (2017 Notes) ........................................ 1,099 1,099
4.85% notes due 2014 (2014 Notes) ........................................ 1,000 1,000
5.70% notes due 2019 (2019 Notes) ........................................ 998 998
6.40% notes due 2039 (2039 Notes) ........................................ 996 995
6.375% notes due 2037 (2037 Notes) ....................................... 899 899
3.45% notes due October 2020 (October 2020 Notes) . . ......................... 897 —
5.75% notes due 2040 (2040 Notes) ........................................ 696 —
4.95% notes due 2041 (2041 Notes) ........................................ 595 —
6.15% notes due 2018 (2018 Notes) ........................................ 499 499
6.90% notes due 2038 (2038 Notes) ........................................ 499 499
4.50% notes due March 2020 (March 2020 Notes) ............................. 300 —
Other notes .......................................................... 183 182
Total borrowings .................................................... 13,362 10,601
Less current portion.................................................... (2,488) —
Total non-current debt ................................................ $10,874 $10,601
Debt issuances
We issued debt securities in various offerings during the three years ended December 31, 2010, including: in
2010, $300 million principal amount of March 2020 Notes, $700 million principal amount of 2040 Notes,
$900 million principal amount of October 2020 Notes and $600 million principal amount of 2041 Notes; in 2009,
$1.0 billion principal amount of 2019 Notes and $1.0 billion principal amount of 2039 Notes; and in 2008,
$500 million principal amount of 2018 Notes and $500 million principal amount of 2038 Notes. Debt issuance costs
incurred in connection with these debt offerings totaled $17 million, $13 million and $6 million for debt issued in
2010, 2009 and 2008, respectively, and are being amortized over the respective lives of the notes and the related
charge is included in “Interest expense, net” in the Consolidated Statements of Income.
All of these debt securities as well as the 2017 Notes and the 2037 Notes may be redeemed at any time at our
option, in whole or in part, at the principal amount of the notes being redeemed plus accrued interest and a “make-
whole” amount, as defined. In the event of a change in control triggering event, as defined, we may be required to
purchase for cash all or a portion of these debt issuances at a price equal to 101% of the principal amount of the notes
plus accrued interest.
Debt repayments
We repaid $1.0 billion aggregate principal amount of notes with a fixed interest rate of 4.00% in 2009 and
$2.0 billion aggregate principal amount of floating London Interbank Offered Rate (“LIBOR”) based notes in 2008.
No debt was due or repaid in 2010.
F-26
AMGEN INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)